Following the identification in our archive of an activating RAF1-fusion melanoma that responded to therapy with a MEK inhibitor [21], we performed a search of our archive of 276,645 clinical samples to identify melanoma cases with RAF1 fusions that created known or likely activating structural variants in RAF1, defined as loss of the autoinhibitory domain but retention of the kinase domain. This evidence concerns the gene MAP2K7 and melanoma.